Radius 
Welcome,         Profile    Billing    Logout  
 5 Products   2 Diseases  5 Products   25 Trials   1248 News 
34 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Orserdu (elacestrant) / Menarini
EMERALD, NCT03778931 / 2018-002990-24: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Completed
3
478
Europe, Canada, US, RoW
Elacestrant, RAD1901, Standard of Care, Faslodex, Arimidex, Femara, Aromasin
Stemline Therapeutics, Inc.
Breast Cancer
08/21
08/24
ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting
3
4220
Europe, Canada, US, RoW
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Stemline Therapeutics, Inc.
Breast Cancer
08/29
10/32
ADELA, NCT06382948: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Recruiting
3
240
Europe
Everolimus, Zortress, Votubia, RAD001, Certican, Afinitor, Elacestrant, ER-306323, RAD1901, Selective estrogen receptor degrader/selective estrogen receptor modulator (SERD/SERM) RAD1901, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
MedSIR, Stemline Therapeutics, Inc.
Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
09/27
04/28
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
ELCIN, NCT05596409: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Active, not recruiting
2
61
Europe, US, RoW
Elacestrant
Stemline Therapeutics, Inc.
Metastatic Breast Cancer
01/26
07/27
NCT06062498: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Not yet recruiting
2
174
US
elacestrant, palbociclib, abemaciclib, ribociclib
Northwestern University, National Cancer Institute (NCI)
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
07/24
07/25
SOLTI-2104, NCT05982093: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Active, not recruiting
2
48
Europe
Elacestrant, Orserdu, Triptorelin
SOLTI Breast Cancer Research Group
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
06/25
02/26
ELEMENT, NCT06201234: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

Recruiting
2
176
Europe
Olaparib + Elacestrant, Olaparib
German Breast Group, Stemline Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
12/28
12/28
NCT06923527: ctDNA Guided Adjuvant Treatment With Elacestrant: TBCRC-068

Not yet recruiting
2
50
US
Elacestrant
Yale University, Johns Hopkins University, Stemline Therapeutics, Inc.
ER+ Breast Cancer
06/27
06/27
HELP, NCT07005882: Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Not yet recruiting
2
21
Europe
Elacestrant, PULSAR
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer Patients, Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR+/HER2- Breast Cancer, Radiation Therapy
03/27
03/28
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Recruiting
2
500
US
AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant, PARPi, Poly(ADP-ribose) inhibitor (PARPi), Olaparib, Talazoparib, AKT inhibitor, Capivasertib, Protein kinase B (AKT) Inhibitor, Step 3 Arm 2
University of Miami
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
07/26
07/29
RECAST-DCIS, NCT06075953: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Recruiting
2
400
US
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, T+Ai, Elacestrant, Z-endoxifen
QuantumLeap Healthcare Collaborative
Ductal Carcinoma in Situ
11/28
11/33
2022-001087-10: This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a randomized Phase 2 evaluation of elacestrant alone or in combination with abemaciclib in women and men with brain metastases from ER positive, HER-2 negative breast cancer. Este estudio tiene 2 fases: una evaluación de Fase 1b de elacestrant en combinación con abemaciclib seguida de una evaluación randomizada de Fase 2 de elacestrant solo o en combinación con abemaciclib en mujeres y hombres con metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y HER-2 negativo.

Not yet recruiting
1/2
106
Europe
Elacestrant, Abemaciclib, LY2835219, Film-coated tablet, Verzenios®
Stemline Therapeutics, Inc, Stemline Therapeutics Inc., Stemline Therapeutics, Inc
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer Metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y negativo para HER-2, Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer Metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y negativo para HER-2, Diseases [C] - Cancer [C04]
 
 
NCT06938711: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Withdrawn
1/2
US
Elacestrant, RAD1901, Onapristone
Context Therapeutics Inc.
Breast Cancer
11/23
12/23
Lilly-I3Y-US-I026, NCT04791384: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Recruiting
1/2
44
US
Abemaciclib, Verzenio, Elacestrant
Criterium, Inc.
Breast Cancer
12/24
01/25
NCT05573126: Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting
1/2
60
Europe, US
Vosilasarm, EP0062, Elacestrant, Everolimus
Ellipses Pharma
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
11/25
11/26
SUMIT-ELA, NCT05963997: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Active, not recruiting
1/2
49
Europe, US
Samuraciclib, Elacestrant Dihydrochloride, ORSERDU
Carrick Therapeutics Limited, Berlin-Chemie AG Menarini Group
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
12/25
12/25
ELONA, NCT05618613: Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Terminated
1/2
4
US
Elacestrant, RAD1901, Onapristone
Context Therapeutics Inc.
Breast Cancer
06/23
06/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT06126575: A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

Recruiting
1
16
US
Elacestrant dihydrochloride
Stemline Therapeutics, Inc.
Hepatic Impairment
11/24
12/24
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
NCT06691035: Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Recruiting
1
18
US
Elacestrant, Oserdu, DC1 native/mutated ESR1
H. Lee Moffitt Cancer Center and Research Institute, The V Foundation for Cancer Research
Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
11/26
11/27
NCT06120283: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Recruiting
1
300
Europe, Japan, US, RoW
BGB-43395, Fulvestrant, Letrozole, Elacestrant
BeiGene
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
06/28
06/28
NCT06544577: Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting
N/A
350
RoW
ELacestrant
SciClone Pharmaceuticals
ESR1 Gene Mutation, Advanced Breast Cancer, Safety
08/25
08/26
Tymlos (abaloparatide) / Radius
NCT04467983: Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Active, not recruiting
4
70
US
Denosumab Injection, Prolia, Abaloparatide, Tymlos
Hospital for Special Surgery, New York, Radius Health, Inc., Crozer-Keystone Health System
Osteoporosis, Postmenopausal
09/26
12/26
NCT04167163: Abaloparatide Before Total Knee Arthroplasty

Completed
4
58
US
Abaloparatide, Tymlos
University of Wisconsin, Madison, Radius Health, Inc.
Osteoporosis, Arthroplasties, Knee Replacement
04/25
04/25
NCT06154187: Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Not yet recruiting
3
60
RoW
PBK_L2201, Placebo
Pharmbio Korea Co., Ltd.
Osteoporosis
05/25
11/25
NCT03841058: Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Recruiting
2
96
US
Abaloparatide, Tymlos, Placebo, placebo pen
Hospital for Special Surgery, New York
Spinal Fusion
09/26
09/26
NCT04249232: Abaloparatide and Pelvic Fracture Healing

Completed
2
48
US
Abaloparatide 80 micrograms per Pen dose, Tymlos, Placebo prefilled injector pen, placebo
Hospital for Special Surgery, New York, Weill Medical College of Cornell University, Icahn School of Medicine at Mount Sinai, New York University, Westchester Medical Center
Fracture of Pelvis (Disorder)
04/24
04/24
NCT04760782: PTH Analog Type II Odontoid Fracture

Terminated
2
22
US
Abaloparatide, Tymlos, Hard collar immobilization
David Lunardini, University of Vermont
Odontoid Fracture
08/23
08/23
NCT06753864: A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

Not yet recruiting
1
32
RoW
Test (T), Reference (R)
The Affiliated Hospital of Qingdao University
Osteoporosis
01/25
05/25
NCT04974723: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Completed
N/A
22054
US
Abaloparatide, Tymlos, Teriparatide, Forteo
Radius Health, Inc., PRA Health Sciences
Osteoporosis, Postmenopausal
09/21
09/21
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment

Recruiting
N/A
150
Europe
Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo, Abaloparatide Injection (80 mcg)
424 General Military Hospital
Osteoporosis, Postmenopausal
12/26
05/27
vosilasarm (EP0062) / Ellipses Pharma
No trials found
estrogen receptor beta-selective agonist / Radius
No trials found
cannabidiol oral solution (RAD011) / Radius, Benuvia Therap
No trials found
abaloparatide transdermal patch (BA-058-TD) / Radius
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Orserdu (elacestrant) / Menarini
EMERALD, NCT03778931 / 2018-002990-24: Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer

Completed
3
478
Europe, Canada, US, RoW
Elacestrant, RAD1901, Standard of Care, Faslodex, Arimidex, Femara, Aromasin
Stemline Therapeutics, Inc.
Breast Cancer
08/21
08/24
ELEGANT, NCT06492616: A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

Recruiting
3
4220
Europe, Canada, US, RoW
Elacestrant, Anastrozole, Letrozole, Exemestane, Tamoxifen
Stemline Therapeutics, Inc.
Breast Cancer
08/29
10/32
ADELA, NCT06382948: Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

Recruiting
3
240
Europe
Everolimus, Zortress, Votubia, RAD001, Certican, Afinitor, Elacestrant, ER-306323, RAD1901, Selective estrogen receptor degrader/selective estrogen receptor modulator (SERD/SERM) RAD1901, Placebo, Auxiliary Medicinal Product - Dexamethasone, Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues
MedSIR, Stemline Therapeutics, Inc.
Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
09/27
04/28
TREAT ctDNA, NCT05512364: Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse

Recruiting
3
220
Europe
Elacestrant, Tamoxifen, Letrozole 2.5mg, Anastrozole 1mg, Exemestane 25 MG
European Organisation for Research and Treatment of Cancer - EORTC, Breast International Group, Menarini Group
ER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
07/28
05/30
ELCIN, NCT05596409: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Active, not recruiting
2
61
Europe, US, RoW
Elacestrant
Stemline Therapeutics, Inc.
Metastatic Breast Cancer
01/26
07/27
NCT06062498: Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer

Not yet recruiting
2
174
US
elacestrant, palbociclib, abemaciclib, ribociclib
Northwestern University, National Cancer Institute (NCI)
Estrogen-receptor-positive Breast Cancer, HER2/Neu-Negative Breast Cancer, Advanced Breast Cancerv, Metastatic Breast Cancer
07/24
07/25
SOLTI-2104, NCT05982093: Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer

Active, not recruiting
2
48
Europe
Elacestrant, Orserdu, Triptorelin
SOLTI Breast Cancer Research Group
Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
06/25
02/26
ELEMENT, NCT06201234: Evaluating the Addition of Elacestrant (oral SERD) to Olaparib (PARP-inhibitor) in Patients with Advanced/metastatic HR+/HER2- Breast Cancer

Recruiting
2
176
Europe
Olaparib + Elacestrant, Olaparib
German Breast Group, Stemline Therapeutics, Inc.
Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
12/28
12/28
NCT06923527: ctDNA Guided Adjuvant Treatment With Elacestrant: TBCRC-068

Not yet recruiting
2
50
US
Elacestrant
Yale University, Johns Hopkins University, Stemline Therapeutics, Inc.
ER+ Breast Cancer
06/27
06/27
HELP, NCT07005882: Hormonal Receptor (HR)-Positive HER2 Negative Breast Cancer Patients Treated With Preoperative ELacestrant and PULSAR Radiotherapy

Not yet recruiting
2
21
Europe
Elacestrant, PULSAR
Azienda Ospedaliero-Universitaria Careggi
Breast Cancer Patients, Breast Cancer Early Stage Breast Cancer (Stage 1-3), HR+/HER2- Breast Cancer, Radiation Therapy
03/27
03/28
NCT05826964: Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

Recruiting
2
500
US
AI+CDK4/6i, Aromatase Inhibitor (AI) + Cyclin dependent kinase 4 and 6 inhibitor (CDK4/6i), Anastrozole, Letrozole, Exemestane, Palbociclib, Ribociclib, Abemaciclib, SERD+CDK4/6i, Selective Estrogen Receptor Degrader (SERD) + CDK4/6i, Fulvestrant, mTOR inhibitor + AI, Mammalian target of rapamycin (mTOR) inhibitor + Aromatase Inhibitor (AI), Everolimus, mTOR inhibitor + SERD, mTOR inhibitor + Selective estrogen receptor modulator, Tamoxifen, PI3K inhibitor + SERD, Phosphoinositide 3-kinase (PI3K) inhibitor + SERD, Alpelisib, PI3K inhibitor + AI, Chemotherapy, Taxane, Eribulin, Capecitabine, Vinorelbine, Oral SERD, Elacestrant, PARPi, Poly(ADP-ribose) inhibitor (PARPi), Olaparib, Talazoparib, AKT inhibitor, Capivasertib, Protein kinase B (AKT) Inhibitor, Step 3 Arm 2
University of Miami
Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
07/26
07/29
RECAST-DCIS, NCT06075953: DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Recruiting
2
400
US
Tamoxifen, Exemestane, Letrozole, Anastrazole, Testosterone + Anastrazole, T+Ai, Elacestrant, Z-endoxifen
QuantumLeap Healthcare Collaborative
Ductal Carcinoma in Situ
11/28
11/33
2022-001087-10: This study has 2 phases: a Phase 1b evaluation of elacestrant in combination with abemaciclib followed by a randomized Phase 2 evaluation of elacestrant alone or in combination with abemaciclib in women and men with brain metastases from ER positive, HER-2 negative breast cancer. Este estudio tiene 2 fases: una evaluación de Fase 1b de elacestrant en combinación con abemaciclib seguida de una evaluación randomizada de Fase 2 de elacestrant solo o en combinación con abemaciclib en mujeres y hombres con metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y HER-2 negativo.

Not yet recruiting
1/2
106
Europe
Elacestrant, Abemaciclib, LY2835219, Film-coated tablet, Verzenios®
Stemline Therapeutics, Inc, Stemline Therapeutics Inc., Stemline Therapeutics, Inc
Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer Metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y negativo para HER-2, Brain Metastasis from Estrogen Receptor Positive, HER-2 Negative Breast Cancer Metástasis cerebrales causadas por un cáncer de mama con receptores de estrógeno y negativo para HER-2, Diseases [C] - Cancer [C04]
 
 
NCT06938711: A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer

Withdrawn
1/2
US
Elacestrant, RAD1901, Onapristone
Context Therapeutics Inc.
Breast Cancer
11/23
12/23
Lilly-I3Y-US-I026, NCT04791384: Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer

Recruiting
1/2
44
US
Abemaciclib, Verzenio, Elacestrant
Criterium, Inc.
Breast Cancer
12/24
01/25
NCT05573126: Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer

Recruiting
1/2
60
Europe, US
Vosilasarm, EP0062, Elacestrant, Everolimus
Ellipses Pharma
Hormone Receptor-positive Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Metastatic Breast Cancer
11/25
11/26
SUMIT-ELA, NCT05963997: A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Active, not recruiting
1/2
49
Europe, US
Samuraciclib, Elacestrant Dihydrochloride, ORSERDU
Carrick Therapeutics Limited, Berlin-Chemie AG Menarini Group
Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
12/25
12/25
ELONA, NCT05618613: Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer

Terminated
1/2
4
US
Elacestrant, RAD1901, Onapristone
Context Therapeutics Inc.
Breast Cancer
06/23
06/23
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/26
12/28
ELECTRA, NCT05386108 / 2022-001087-10: Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer

Recruiting
1/2
68
Europe, US, RoW
Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio
Stemline Therapeutics, Inc., Stemline Therapeutics, Inc
Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
12/25
12/25
NCT06126575: A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function

Recruiting
1
16
US
Elacestrant dihydrochloride
Stemline Therapeutics, Inc.
Hepatic Impairment
11/24
12/24
NCT06638307: A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

Recruiting
1
124
US
MEN2312, Elacestrant, Orserdu
Stemline Therapeutics, Inc.
Advanced Breast Cancer
10/25
10/26
NCT06691035: Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer

Recruiting
1
18
US
Elacestrant, Oserdu, DC1 native/mutated ESR1
H. Lee Moffitt Cancer Center and Research Institute, The V Foundation for Cancer Research
Breast Cancer Metastatic Breast Cancer, HER2-negative Breast Cancer
11/26
11/27
NCT06120283: BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

Recruiting
1
300
Europe, Japan, US, RoW
BGB-43395, Fulvestrant, Letrozole, Elacestrant
BeiGene
Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer
06/28
06/28
NCT06544577: Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC

Recruiting
N/A
350
RoW
ELacestrant
SciClone Pharmaceuticals
ESR1 Gene Mutation, Advanced Breast Cancer, Safety
08/25
08/26
Tymlos (abaloparatide) / Radius
NCT04467983: Abaloparatide Added to Ongoing Denosumab vs Continued Denosumab Alone

Active, not recruiting
4
70
US
Denosumab Injection, Prolia, Abaloparatide, Tymlos
Hospital for Special Surgery, New York, Radius Health, Inc., Crozer-Keystone Health System
Osteoporosis, Postmenopausal
09/26
12/26
NCT04167163: Abaloparatide Before Total Knee Arthroplasty

Completed
4
58
US
Abaloparatide, Tymlos
University of Wisconsin, Madison, Radius Health, Inc.
Osteoporosis, Arthroplasties, Knee Replacement
04/25
04/25
NCT06154187: Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis

Not yet recruiting
3
60
RoW
PBK_L2201, Placebo
Pharmbio Korea Co., Ltd.
Osteoporosis
05/25
11/25
NCT03841058: Abaloparatide vs. Placebo in Post-Menopausal Women and Abaloparatide in Men Receiving Initial Spinal Fusion Surgery

Recruiting
2
96
US
Abaloparatide, Tymlos, Placebo, placebo pen
Hospital for Special Surgery, New York
Spinal Fusion
09/26
09/26
NCT04249232: Abaloparatide and Pelvic Fracture Healing

Completed
2
48
US
Abaloparatide 80 micrograms per Pen dose, Tymlos, Placebo prefilled injector pen, placebo
Hospital for Special Surgery, New York, Weill Medical College of Cornell University, Icahn School of Medicine at Mount Sinai, New York University, Westchester Medical Center
Fracture of Pelvis (Disorder)
04/24
04/24
NCT04760782: PTH Analog Type II Odontoid Fracture

Terminated
2
22
US
Abaloparatide, Tymlos, Hard collar immobilization
David Lunardini, University of Vermont
Odontoid Fracture
08/23
08/23
NCT06753864: A Single-center, Open, Randomized, Single-dose, Cross-over Bioequivalence Study to Evaluate the Effects of the Test Formulation Abalparatide Injection and the Reference Formulation Abalparatide Injection (Tymlos®) in Healthy Adult Subjects

Not yet recruiting
1
32
RoW
Test (T), Reference (R)
The Affiliated Hospital of Qingdao University
Osteoporosis
01/25
05/25
NCT04974723: Real-world Effectiveness and Cardiovascular Safety Study of Abaloparatide in Postmenopausal Women

Completed
N/A
22054
US
Abaloparatide, Tymlos, Teriparatide, Forteo
Radius Health, Inc., PRA Health Sciences
Osteoporosis, Postmenopausal
09/21
09/21
START, NCT06164795: Sequential Therapies After Osteoanabolic Treatment

Recruiting
N/A
150
Europe
Zoledronate, zoledronic acid; zolendronate, Denosumab, Dmab, Teriparatide, TPTD, Romosozumab, Romo, Abaloparatide Injection (80 mcg)
424 General Military Hospital
Osteoporosis, Postmenopausal
12/26
05/27
vosilasarm (EP0062) / Ellipses Pharma
No trials found
estrogen receptor beta-selective agonist / Radius
No trials found
cannabidiol oral solution (RAD011) / Radius, Benuvia Therap
No trials found
abaloparatide transdermal patch (BA-058-TD) / Radius
No trials found

Download Options